Moroxite advances to stage 2 of European Innovation Council's Accelerator Programme with Xerafuse™

Moroxite has successfully cleared Stage 1 of the EIC Accelerator programme for our innovative product, Xerafuse™. This bone mineral granule, combined with BMP-2, is designed for use in spinal fusion and has the potential to replace autograft transplantation, offering a safer and more effective solution with a lower BMP-2 dose compared to existing carriers and technologies.

Xerafuse is currently in the late preclinical stage, with clinical studies being planned.